Navigation Links
FDA Approves Adcetris to Treat Two Types of Lymphoma
Date:8/19/2011

SILVER SPRING, Md., Aug. 19, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Lymphomas are cancers of the lymphatic system. Adcetris is an antibody-drug conjugate that combines an antibody and drug, allowing the antibody to direct the drug to a target on lymphoma cells known as CD30.

Adcetris is to be used in patients with HL whose disease has progressed after autologous stem cell transplant or after two prior chemotherapy treatments for those who cannot receive a transplant. Autologous stem cell transplant is a procedure using a patient's own bone marrow that is designed to repair damaged bone marrow after the use of high chemotherapy doses. Adcetris may also be used in patients with ALCL whose disease has progressed after one prior chemotherapy treatment.

"Early clinical data suggest that patients who received Adcetris for Hodgkin lymphoma and systemic anaplastic lymphoma experienced a significant response to the therapy," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research.

According to the National Cancer Institute (NCI), common symptoms of HL include the enlargement of lymph nodes, spleen, fever, weight loss, fatigue, or night sweats. NCI estimates that 8,830 new cases of HL will be diagnosed in the United States in 2011 and about 1,300 people will die from the disease.

Systemic ALCL is a rare malignant tumor (non-Hodgkin lymphoma) that may appear in several parts of the body including the lymph nodes, skin, bones, soft tissue, lungs or liver, according to the NCI.

Adcetris is the first new FDA-approved treatment for HL since 1977 and the first specifically indicated to treat ALCL.

The effective
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Most osteoporosis patients want a ... recent online survey* sponsored by Mission Pharmacal Company. The ... Osteoporosis Foundation online support community, revealed that 74 percent ... comes in a form other than a pill or ...
(Date:1/15/2014)... Jan. 15, 2014 AARP Foundation today announced it has ... suffering from the severe cold weather that has gripped much ... helping those in need; so to support these emergency relief ... to $250,000, which could mean up to $500,000 in aid. ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Implicit Bioscience Ltd and CMC ICOS Biologics today announced ... next stage of development and commercialization of IC14, a ... IC14 has a demonstrated safety profile in over 150 ... trial in mechanically-ventilated patients has provided a clear rationale ...
... Science is largely a collaborative enterprise. Frequently researchers ... pool their efforts and exchange ideas, to devise ... such as those known as autism spectrum disorders, ... on diverse populations of patients, finding a broader ...
Cached Medicine Technology:CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License 2CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License 3CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License 4Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 2Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 3Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 4
(Date:7/12/2014)... New York, New York (PRWEB) July 12, 2014 ... involving liver damage allegations continue to move forward ... District Court, Eastern District of Pennsylvania, Bernstein Liebhard ... 1, 2014, U.S. District Judge Lawrence F. Stengel ... president. Among other things, Judge Stengel found that ...
(Date:7/12/2014)... News) -- Burn injuries increase in the summer as people ... experts. Among those most vulnerable to these seasonal fire hazards: ... often get burned by putting their hands on the side ... burn unit at Loyola University Medical Center in Maywood, Ill., ... of ,When you play with fire, you get burned, is ...
(Date:7/12/2014)... July 12, 2014 “After my mom’s stroke, she ... a stroke and loss the use of his left side. Eating ... a way to help people like them enjoy eating again,” said ... prototype for the PATRICIA CAROL HALL PLATE (P C H PLATE). ... a more ergonomic way to eat for individuals who suffer from ...
(Date:7/12/2014)... 12, 2014 With prom shopping reaching ... and retailer, is ready to showcase its new and ... collection of evening dresses in its online shop. Additionally, ... off) for these elegant gowns. According to the company’s ... on July 26, 2014. , He says, “Now, ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 “Critical ... - New and Late-Stage Four-Factor PCCs and Recombinant ... of the critical care market in the US, ... The report provides an estimation of market size ... It covers critical care indications that are being ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... At the 54th Annual Meeting of SNM, the ... medicine professionals, German researchers stated that early ... identifies patients responding to chemotherapy for esophageal cancer. ... apply PET results from early metabolic response assessment ...
... Secretary Mike Leavitt announced today that HHS has awarded a ... Denmark to manufacture and deliver 20 million doses of ... ,The vaccine would be recommended in the event of ... who have weakened immune systems. The full supply of the ...
... Center for Consumer Freedom (CCF) welcomed a new study ... & Adolescent Medicine, which will contribute to the steadily ... television food advertising and childhood obesity. A report issued ... similar results. ,The Archives study found that ...
... Pharmion Corporation today released interim findings from its ... company's third-generation synthetic anthracycline currently in development ... ,These findings indicate favorable interim results ... comparing Amrubicin to the current treatment standard, topotecan, ...
... by researchers at the Duke University Medical Center has found ... 3-fatty acids and fiber-related compounds known as lignans, is ... also think that the seed, which is similar to a ... events that leads cells to divide irregularly and become cancerous. ...
... why some people get anxious, or really scared when faced ... Well researchers at the European Molecular Biology Laboratory (EMBL) ... a new research they conducted on mice. ,They ... that could be potentially dangerous but not necessarily so, as ...
Cached Medicine News:Health News:Esophageal Cancer Patients' Positive Responses to Chemotherapy Accurately Identified by PET 2Health News:HHS Buys Next Generation Smallpox Vaccine 2Health News:HHS Buys Next Generation Smallpox Vaccine 3Health News:New Studies: Commercials Aren't Making Kids Fat 2Health News:Amrubicin Shows Encouraging Results for Small Cell Lung Cancer Treatment 2Health News:Flaxseed Helps in Reducing the Risk of Prostate Tumor Spread 2Health News:Researchers Have Found Clue to How Fear Changes into Phobia 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: